Intestinal fibrosis, which is usually the consequence of chronic inflammation, is a common
complication of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative …

Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract,
but possibly other gastrointestinal and extraintestinal organs. Although etiology is still …

Background Complex perianal fistulas in Crohn's disease are challenging to treat.
Allogeneic, expanded, adipose-derived stem cells (Cx601) are a promising new therapeutic …

In the United States, approximately 0.5% of the population, or 1.6 million people, have
inflammatory bowel disease (IBD)—Crohn's disease (CD) and ulcerative colitis (UC). 1, 2 Of …

Background & Aims The management of inflammatory bowel disease (IBD) poses a
particular challenge during pregnancy because the health of both the mother and the fetus …

Patients with a diverse spectrum of rare genetic disorders can present with inflammatory
bowel disease (monogenic IBD). Patients with these disorders often develop symptoms …

Summary Background Most patients with Crohn's disease need an intestinal resection, but a
majority will subsequently experience disease recurrence and require further surgery. This …

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with
increasing incidence worldwide. Crohn's disease might result from a complex interplay …

Recent studies have identified mucosal healing on endoscopy as a key prognostic
parameter in the management of inflammatory bowel diseases (IBD), thus highlighting the …

Six biologic agents are currently approved for the treatment of IBD: four anti-TNF agents
(infliximab, adalimumab, golimumab and certolizumab pegol) and two anti-integrin agents …